See the DrugPatentWatch profile for Adalimumab
Adalimumab adalimum is a biosimilar to Humira, a medication used to treat conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis [1]. Biosimilars are highly similar to existing biologic medicines and have no clinically meaningful differences in terms of safety, purity, and effectiveness [2].
What conditions does adalimumab adalimum treat?
Adalimumab adalimum is indicated for the treatment of several chronic inflammatory diseases. These include moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis [1]. It is also used for moderate to severe plaque psoriasis and active polyarticular juvenile idiopathic arthritis [1].
How does adalimumab adalimum work?
This medication belongs to a class of drugs called tumor necrosis factor (TNF) blockers [1]. TNF is a protein that plays a significant role in the inflammatory processes of the body. Adalimumab adalimum works by inhibiting the activity of TNF, thereby reducing inflammation and alleviating symptoms associated with the aforementioned autoimmune diseases [1].
When does the patent for Humira expire?
Humira's primary patents have largely expired, allowing for the development and introduction of biosimilars [3]. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals.
What is the difference between adalimumab adalimum and Humira?
Adalimumab adalimum is a biosimilar, meaning it is highly similar to Humira and has been shown to have no clinically meaningful differences in safety, purity, and effectiveness [2]. The key difference lies in their manufacturing processes and origin; Humira is the reference product, while adalimumab adalimum is a separately approved biologic product that demonstrates this similarity.
Who makes adalimumab adalimum?
Several companies have developed and market adalimumab biosimilars. These include AbbVie (the manufacturer of Humira), Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Hadlima), and others [4].
What are the potential side effects of adalimumab adalimum?
Like other TNF blockers, adalimumab adalimum can have side effects. Common side effects may include infections (such as upper respiratory infections, sinus infections, and urinary tract infections), injection site reactions, rash, and nausea [1]. More serious side effects can include severe infections, nervous system problems, heart failure, and an increased risk of certain cancers [1]. Patients should discuss potential risks with their healthcare provider.
Can adalimumab adalimum be used by children?
Yes, adalimumab adalimum is approved for the treatment of active polyarticular juvenile idiopathic arthritis in patients aged four years and older [1].
What clinical data supports adalimumab adalimum's effectiveness?
Biosimilars undergo rigorous clinical studies to demonstrate their similarity to the reference product. These studies typically involve pharmacokinetic and pharmacodynamic assessments, as well as immunogenicity studies [2]. Comparative clinical trials are also conducted to confirm no clinically meaningful differences in safety and efficacy.
How does adalimumab adalimum compare to other adalimumab biosimilars?
While all adalimumab biosimilars are designed to be highly similar to Humira, subtle differences in their exact composition or manufacturing may exist. However, regulatory agencies approve them only after extensive data proves their biosimilarity, ensuring they offer comparable therapeutic outcomes [2]. Patients should consult with their physician regarding the specific biosimilar prescribed.